

SEQUENCE LISTING

<110> Alkermes Pharma Ireland Limited
LOSEY, Heather C.
LOPES, Jared
SUN, Lei
WINQUIST, Raymond J.

<120> Compositions and Methods for Subcutaneous Administration of Cancer Immunotherapy

<130> P136792W0 (4165.3081 W0)

<140> PCT/EP2020/066234

<141> 2020-06-11

<150> 62/860,182

<151> 2019-06-11

<150> 62/924,356

<151> 2019-10-22

<150> 62/932,160

<151> 2019-11-07

<160> 3

<170> PatentIn version 3.5

<210> 1

<211> 303

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<400> 1

Ser	Lys	Asn	Phe	His	Leu	Arg	Pro	Arg	Asp	Leu	Ile	Ser	Asn	Ile	Asn
1				5					10					15	

Val	Ile	Val	Leu	Glu	Leu	Lys	Gly	Ser	Glu	Thr	Thr	Phe	Met	Cys	Glu
			20					25					30		

Tyr	Ala	Asp	Glu	Thr	Ala	Thr	Ile	Val	Glu	Phe	Leu	Asn	Arg	Trp	Ile
		35					40					45			

Thr	Phe	Ser	Gln	Ser	Ile	Ile	Ser	Thr	Leu	Thr	Gly	Gly	Ser	Ser	Ser
	50					55					60				

Thr Lys Lys Thr Gln Leu Gln Leu Glu His Leu Leu Leu Asp Leu Gln
65 70 75 80

Met Ile Leu Asn Gly Ile Asn Asn Tyr Lys Asn Pro Lys Leu Thr Arg
85 90 95

Met Leu Thr Phe Lys Phe Tyr Met Pro Lys Lys Ala Thr Glu Leu Lys
100 105 110

His Leu Gln Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Val Leu
115 120 125

Asn Leu Ala Gln Gly Ser Gly Gly Gly Ser Glu Leu Cys Asp Asp Asp
130 135 140

Pro Pro Glu Ile Pro His Ala Thr Phe Lys Ala Met Ala Tyr Lys Glu
145 150 155 160

Gly Thr Met Leu Asn Cys Glu Cys Lys Arg Gly Phe Arg Arg Ile Lys
165 170 175

Ser Gly Ser Leu Tyr Met Leu Cys Thr Gly Asn Ser Ser His Ser Ser
180 185 190

Trp Asp Asn Gln Cys Gln Cys Thr Ser Ser Ala Thr Arg Asn Thr Thr
195 200 205

Lys Gln Val Thr Pro Gln Pro Glu Glu Gln Lys Glu Arg Lys Thr Thr
210 215 220

Glu Met Gln Ser Pro Met Gln Pro Val Asp Gln Ala Ser Leu Pro Gly
225 230 235 240

His Cys Arg Glu Pro Pro Pro Trp Glu Asn Glu Ala Thr Glu Arg Ile
245 250 255

Tyr His Phe Val Val Gly Gln Met Val Tyr Tyr Gln Cys Val Gln Gly
260 265 270

Tyr Arg Ala Leu His Arg Gly Pro Ala Glu Ser Val Cys Lys Met Thr

275

280

285

His Gly Lys Thr Arg Trp Thr Gln Pro Gln Leu Ile Cys Thr Gly
 290 295 300

<210> 2

<211> 309

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic peptide

<400> 2

Ser Lys Ser Phe Gln Leu Glu Asp Ala Glu Asn Phe Ile Ser Asn Ile
 1 5 10 15

Arg Val Thr Val Val Lys Leu Lys Gly Ser Asp Asn Thr Phe Glu Cys
 20 25 30

Gln Phe Asp Asp Glu Ser Ala Thr Val Val Asp Phe Leu Arg Arg Trp
 35 40 45

Ile Ala Phe Cys Gln Ser Ile Ile Ser Thr Ser Pro Gln Gly Gly Ser
 50 55 60

Ser Ser Thr Gln Gln Gln Gln His Leu Glu Gln Leu Leu Met Asp
 65 70 75 80

Leu Gln Glu Leu Leu Ser Arg Met Glu Asn Tyr Arg Asn Leu Lys Leu
 85 90 95

Pro Arg Met Leu Thr Phe Lys Phe Tyr Leu Pro Lys Gln Ala Thr Glu
 100 105 110

Leu Lys Asp Leu Gln Cys Leu Glu Asp Glu Leu Gly Pro Leu Arg His
 115 120 125

Val Leu Asp Leu Thr Gln Gly Ser Gly Gly Gly Ser Glu Leu Cys Leu
 130 135 140

Tyr Asp Pro Pro Glu Val Pro Asn Ala Thr Phe Lys Ala Leu Ser Tyr

145		150		155		160									
Lys	Asn	Gly	Thr	Ile	Leu	Asn	Cys	Glu	Cys	Lys	Arg	Gly	Phe	Arg	Arg
				165					170					175	
Leu	Lys	Glu	Leu	Val	Tyr	Met	Arg	Cys	Leu	Gly	Asn	Ser	Trp	Ser	Ser
			180					185					190		
Asn	Cys	Gln	Cys	Thr	Ser	Asn	Ser	His	Asp	Lys	Ser	Arg	Lys	Gln	Val
		195					200					205			
Thr	Ala	Gln	Leu	Glu	His	Gln	Lys	Glu	Gln	Gln	Thr	Thr	Thr	Asp	Met
	210					215					220				
Gln	Lys	Pro	Thr	Gln	Ser	Met	His	Gln	Glu	Asn	Leu	Thr	Gly	His	Cys
225					230					235					240
Arg	Glu	Pro	Pro	Pro	Trp	Lys	His	Glu	Asp	Ser	Lys	Arg	Ile	Tyr	His
				245					250					255	
Phe	Val	Glu	Gly	Gln	Ser	Val	His	Tyr	Glu	Cys	Ile	Pro	Gly	Tyr	Lys
			260					265					270		
Ala	Leu	Gln	Arg	Gly	Pro	Ala	Ile	Ser	Ile	Cys	Lys	Met	Lys	Cys	Gly
		275					280					285			
Lys	Thr	Gly	Trp	Thr	Gln	Pro	Gln	Leu	Thr	Cys	Val	Asp	Gly	Ser	His
	290					295					300				
His	His	His	His	His											
305															
<210>	3														
<211>	20														
<212>	PRT														
<213>	Artificial Sequence														
<220>															
<223>	Synthetic peptide														
<400>	3														
Met	Tyr	Arg	Met	Gln	Leu	Leu	Ser	Cys	Ile	Ala	Leu	Ser	Leu	Ala	Leu

1

5

10

15

Val Thr Asn Ser
20